Sandoz to build biologics plant in Slovenia
European Pharmaceutical Review
MARCH 13, 2023
Signing of the MOU “sets up Sandoz to expand patients’ access to the large number of biologics losing patent protection over the next few years,” commented Dominic Wake, Head of Market Access and Corporate Affairs at Sandoz. Full operations is provisionally planned for late 2026.
Let's personalize your content